Epigendx sample analysis and RNA QC on bioanalyzer for 56 quantity
Ended Purchase Order Awarded Last action
- Contract number
- 75N91021P00511
- Awardee
-
Epigendx Inc. UEI MTD6MD6HDC63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $20,160
Award facts
- Contract value 100% obligated
- $20,160.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a purchase order to Epigendx Inc., a minority-owned and woman-owned small business, for $20,160.00 on June 11, 2021. The order covers Epigendx sample analysis and RNA quality control on a Bioanalyzer for 56 units. Performance occurs in Rockville, Maryland, with an ultimate completion date of July 10, 2021. The contract is priced on a firm fixed-price basis.
Quick answers
Who was awarded contract 75N91021P00511?
75N91021P00511 was awarded to Epigendx Inc. by National Cancer Institute (National Institutes of Health) on June 11, 2021.
How much is contract 75N91021P00511 worth?
The government has obligated $20,160 on 75N91021P00511.
Was contract 75N91021P00511 competed?
The extent of competition for 75N91021P00511 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award